OPKO Health (NASDAQ:OPK) Director John Paganelli Sells 9,175 Shares of Company Stock

Key Points

• Director John Paganelli sold 9,175 OPKO shares at an average price of $1.82, receiving about $16,699. He retained 389,914 shares after the sale.
• OPKO reported quarterly EPS of a $0.07 loss, matching analysts’ estimate, while revenue of $130.83 million fell short of expectations and was down 56.9% year over year.
• OPKO agreed to sell most of its remaining BioReference diagnostic operations to Labcorp for $722 million in cash, with the proceeds expected to support liquidity as the company focuses on biotech.

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) Director John Paganelli sold 9,175 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $1.82, for a total transaction of $16,698.50. Following the completion of the transaction, the director directly owned 389,914 shares of the company's stock, valued at approximately $709,643.48. The trade was a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OPKO Health Stock Down 1.1%

Shares of NASDAQ OPK traded down $0.02 during mid-day trading on Thursday, hitting $1.75. 9,785,748 shares of the stock traded hands, compared to its average volume of 3,240,198. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -19.44 and a beta of 1.52. The stock has a fifty day moving average price of $1.58 and a 200-day moving average price of $1.35. OPKO Health, Inc. has a 52 week low of $0.98 and a 52 week high of $1.83. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.93 and a current ratio of 3.35.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%. The firm had revenue of $130.83 million for the quarter, compared to analysts' expectations of $136.62 million. During the same period in the previous year, the firm posted $0.03 EPS. The business's revenue for the quarter was down 56.9% compared to the same quarter last year. Research analysts anticipate that OPKO Health, Inc. will post -0.23 EPS for the current year.

Trending Headlines about OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO agreed to sell substantially all of its remaining BioReference diagnostic operations to Labcorp for $722 million in cash. The proceeds could bolster liquidity as OPKO concentrates on its biotech business. OPKO third-quarter results and business highlights
• Positive Sentiment: OPKO’s reported third-quarter loss was $0.05 per share, better than the $0.07 loss analysts expected, according to one estimate. Zacks report on OPKO’s third-quarter results
• Neutral Sentiment: Following the sale agreement, OPKO forecast 2026 revenue from continuing operations of $268 million to $278 million. OPKO’s 2026 continuing-operations revenue outlook
• Negative Sentiment: Reported third-quarter revenue of $65.4 million was well below FactSet’s $136.6 million estimate, although the earnings-call summary characterized revenue as up 16%. Comparisons may reflect the changing business mix following the planned BioReference sale. Q3 revenue report
• Negative Sentiment: Investors also face biotech execution risk: the earnings-call coverage said losses widened and the CAR-T program timeline was delayed, potentially postponing progress on a key part of OPKO’s future growth strategy. Q3 earnings-call highlights

Analyst Upgrades and Downgrades

A number of research firms have issued reports on OPK. Weiss Ratings restated a "sell (d-)" rating on shares of OPKO Health in a research note on Thursday, August 13th. Zacks Research upgraded shares of OPKO Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 28th. HC Wainwright reissued a "buy" rating on shares of OPKO Health in a report on Friday, October 16th. Piper Sandler restated an "overweight" rating and set a $4.00 target price (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. Finally, UBS Group set a $4.00 target price on shares of OPKO Health in a report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, OPKO Health presently has an average rating of "Moderate Buy" and an average price target of $3.42.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of OPKO Health in the 2nd quarter worth $55,468,000. AWM Investment Company Inc. acquired a new position in OPKO Health during the 2nd quarter valued at about $3,165,000. Bank of New York Mellon Corp purchased a new stake in OPKO Health in the second quarter valued at about $1,995,000. Bank of America Corp DE raised its stake in OPKO Health by 80.0% in the first quarter. Bank of America Corp DE now owns 1,141,849 shares of the biotechnology company's stock valued at $1,302,000 after buying an additional 507,590 shares during the last quarter. Finally, Van ECK Associates Corp boosted its holdings in OPKO Health by 174.0% in the second quarter. Van ECK Associates Corp now owns 438,645 shares of the biotechnology company's stock worth $658,000 after acquiring an additional 278,549 shares in the last quarter. Institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.